瑞博生物(6938.HK)今起招股，入场费11710港元

Group 1 - The core point of the article is that Rebio Biotech-B (6938.HK) is launching an IPO from today until January 6, 2026, with a share price of HKD 57.97 and plans to raise up to HKD 1.593 billion [1] - The offering consists of 27.4874 million shares, with approximately 10% allocated for public sale in Hong Kong and the remainder for international placement [1] - The expected listing date for the stock is January 9, 2026 [1] Group 2 - Approximately 37.4% of the net proceeds from the fundraising will be allocated to the research and development of the core product RBD4059 [1] - About 19.6% of the funds will be used for the development of RBD5044 [1] - Approximately 15.9% will be directed towards the research of RBD1016 [1] - Around 10.1% will finance pipeline assets that are in the preclinical trial application stage [1] - About 8.9% will be allocated to advance preclinical assets that have not yet entered the preclinical trial application stage and to enhance the technology platform [1] - Approximately 8.1% will be used for working capital and other general corporate purposes [1]